Drug news
Afatinib(Boehringer) enters Phase III trials for Head and Neck Cancer
Afatinib from Boehringer enters Phase III trials for Head and Neck cancer.LUX-Head & Neck 1 and LUX-Head & Neck 2. These trials evaluate Afatinib in patients with metastatic and recurrent head and neck cancer, and in patients with locally advanced disease, respectively.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.